Can Novo Nordisk bounce back?

Feb 11, 2013 : Shares in Novo Nordisk fell as much as 15 per cent after the US Food and Drug Administration withheld approval for its new insulin treatment pending further tests. With a quick approval previously priced into its stock, the decision came as a shock to the company. Lex's Julia Grindell and Vincent Boland consider whether the group's shares are now fairly priced, and the impact of the decision on this year's earnings.
1 - 12 COMPANIES & MANAGEMENT (30)